CRISPR / Cas9 System and Its Application in Tumor Therapy

被引:0
|
作者
Qiao Huan-Huan [1 ]
Zhang Qing-Hao [1 ]
Ming Dong [1 ]
机构
[1] Tianjin Univ, Acad Med Engn & Translat Med, Tianjin 300072, Peoples R China
基金
中国博士后科学基金;
关键词
CRISPR/Cas9; gene editing; nano carrier; tumor treatment; IN-VIVO; MESSENGER-RNA; DELIVERY; GENE; CELLS; RIBONUCLEOPROTEIN; VITRO; GENERATION; KNOCKOUT; IMMUNITY;
D O I
10.16476/j.pibb.2020.0239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The emerging CRISPR/Cas9 gene editing technology can realize the manipulation of genes at the molecular level. It has the advantages of simple design, easy operation, good specificity and high efficiency. It is widely used in the study of potential mechanisms of tumorigenesis, development and metastasis and clinical treatment. Recent researches into the use of CRISPR/Cas9 for tumor therapy in vivo have focused on developing vectors. Non-viral nano-carriers developed by nanotechnology can efficiently deliver the CRISPR/Cas9 system into the body, providing a new way for the clinical application of CRISPR/Cas9 technology. In this review, we discuss the principle of CRISPR/Cas9, the current delivery forms of CRISPR/Cas9 and commonly used nanodelivery vectors. We highlight several nano-carriers including inorganic nanoparticles, polymer-based nanoparticles, lipid-based nanoparticles and others. We also summarize the characteristics, editing efficiency, applications and new studies of different nano-carriers. The applications and progresses of CRISPR/Cas9 in treating different tumors are also discussed.
引用
收藏
页码:570 / 579
页数:10
相关论文
共 45 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] Endosomal Escape and Delivery of CRISPR/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework
    Alsaiari, Shahad K.
    Patil, Sachin
    Alyami, Mram
    Alamoudi, Kholod O.
    Aleisa, Fajr A.
    Merzaban, Jasmeen S.
    Li, Mo
    Khashab, Niveen M.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2018, 140 (01) : 143 - 146
  • [3] [Anonymous], 2017, LANCET, DOI [10.1001/jamaoncol.2019.2996, DOI 10.1016/S0140-6736(16)31891-8]
  • [4] Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics
    Chen, Fengqian
    Alphonse, Martin
    Liu, Qi
    [J]. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2020, 12 (03)
  • [5] CRISPR gene editing tested in a person
    Cyranoski, David
    [J]. NATURE, 2016, 539 (7630) : 479 - 479
  • [6] Viral Vectors, Engineered Cells and the CRISPR Revolution
    DiCarlo, James E.
    Deeconda, Anurag
    Tsang, Stephen H.
    [J]. PRECISION MEDICINE, CRISPR, AND GENOME ENGINEERING: MOVING FROM ASSOCIATION TO BIOLOGY AND THERAPEUTICS, 2017, 1016 : 3 - 27
  • [7] Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b
    El Fatimy, Rachid
    Subramanian, Shruthi
    Uhlmann, Erik J.
    Krichevsky, Anna M.
    [J]. MOLECULAR THERAPY, 2017, 25 (02) : 368 - 378
  • [8] Ganguly D., 2018, ONCOTARGET, V9, P22095, DOI [10.18632/oncotarget.25188, DOI 10.18632/ONCOTARGET.25188]
  • [9] Gasiunas Giedrius, 2012, Proc Natl Acad Sci U S A, V109, pE2579
  • [10] Poly-sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption
    Ha, Jong Seong
    Lee, Jae Sung
    Jeong, Jaepil
    Kim, Hejin
    Byun, Juyoung
    Kim, Sang Ah
    Lee, Hee Jae
    Chung, Hak Suk
    Lee, Jong Bum
    Ahn, Dae-Ro
    [J]. JOURNAL OF CONTROLLED RELEASE, 2017, 250 : 27 - 35